Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination dietary supplement containing forskolin (from Coleus forskohlii extract), rutin, vitamin B1 (thiamine), and vitamin B2 (riboflavin). It is primarily marketed as an adjunctive therapy for patients with primary open-angle glaucoma (POAG). Forskolin acts by increasing cyclic AMP levels, leading to reduced aqueous humor inflow and lower intraocular pressure. Rutin is a flavonoid with antioxidant properties that may improve ocular blood flow. Vitamins B1 and B2 are included for their general neuroprotective and metabolic support roles. Clinical studies have shown that this combination can further reduce intraocular pressure in POAG patients already on topical hypotensive medications, as well as provide neuroprotective effects on retinal ganglion cells and improve symptoms of dry eye associated with chronic use of preserved eye drops[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on forskolin + rutin + vitamin B1 + vitamin B2.